

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE








	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa fever	University of Oxford		IAVI		
MERS	Uvax	IDT, Barinthus/University of Oxford			
Nipah		PHV, University of Oxford			
Rift Valley fever	UC Davis, Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
Chikungunya				IVI/Bharat	Valneva
COVID-19*					SK Bioscience, Biological E, Moderna, Clover, Novavax, AZ/Oxford, University of Hong Kong
Broadly protective Betacoronavirus	VIDO, Panacea/THSTI, IVI consortium, CPI/CalTech, Bharat/U Syd/ExcellGene, NEC, SK Bioscience, Intravacc				
Mpox			BioNTech		

(* CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

		Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
<p>Disease X</p>	Akagera	POP BIO	Lemonex			
	Chungbuk University	Gennova*				
	University of Queensland	Emervax				
	Moderna	HMRI				
	SK bio	Imperial				
	University of Oxford	Amplitude				
	Boost Biopharma	Nagasaki University				
	Centivax	VitriVax				
	ACM Bio	Abera Bioscience				
<p>Broadly protective Filovirus vaccines</p>	Adaptvac					

(*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

	DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
	Lassa fever	University of Oxford	Preclinical	Viral Vector	Up to \$19 million‡
		IAVI	Phase 2	Viral Vector	Up to \$64.4 million
	MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million‡
		IDT	Phase I	Viral vector	Up to \$36 million
		Uvax bio	Preclinical	Protein based	Up to \$2.6 million
	Nipah	University of Oxford	Phase I	Viral Vector	Up to \$19 million‡
		PHV	Phase I	Viral vector	Up to \$43.6 million
	Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million
		Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
		University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
		Afrigen	Preclinical	mRNA	Up to \$6.2 million
	Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated virus	Up to \$14.1 million
		Valneva	Registration	Live attenuated	Up to \$65.9 million
	COVID-19	SK Bioscience	Registration	Protein based	Up to \$210 million
		Biological E	Registration	Protein based	Up to \$14 million
		Moderna	Registration	Protein based	Up to \$1 million
		Clover	Registration	Protein based	Up to \$397.4 million
		University of Hong Kong	Registration	Live attenuated	Up to \$5.4 million
		AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
		Novavax	Registration	Protein based	Up to \$399 million
	Mpox	BioNTech	Phase I/II	mRNA	Up to \$72 million***

(‡) Includes Lassa, MERS and Nipah funding

(**) Includes COVID-19 variant and BPBC funding. Project funding complete.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

*** Funding is part of a total investment of up to \$90m.



**Broadly protective
Betacoronavirus**

IVI Consortium	Preclinical	mRNA	Up to \$23.9 million
VIDO	Preclinical	Protein based	Up to \$22 million
Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
CPI/Caltech	Preclinical	Protein based	Up to \$30 million
NEC	Preclinical	RNA	Up to \$4.8 million
SK Bioscience	Preclinical	Protein based	Up to \$50 million
Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
Intravacc	Preclinical	Protein based	Up to \$4.8 million



Disease X

Abera Bioscience	Preclinical	Protein based	Up to \$1.5 million
Akagera	Preclinical	mRNA	Up to \$1.5 million
ACM Bio	Preclinical	mRNA	Up to \$2.9 million
Amplitude	Preclinical	SaRNA	Up to \$1 million
Boost Biopharma	Preclinical	Protein based	Up to \$5 million
Centivax	Preclinical	mRNA	Up to \$5.0 million
Chungbuk National University	Preclinical	SaRNA	Up to \$0.9 million
Emervax	Preclinical	CircRNA	Up to \$2.2 million
Gennova	Preclinical	mRNA	Up to \$16.98 million##
HMRI	Preclinical	CircRNA	Up to \$3.8 million
Imperial College London	Preclinical	SaRNA	Up to \$8.4 million
Lemonex	Phase I	mRNA	Up to \$4.9 million
Moderna	Preclinical	mRNA	Not yet at a stage where CEPI provides funding to Moderna.
Nagasaki University	Preclinical	mRNA	Up to \$5 million
University of Oxford	Preclinical	Viral Vector	Up to \$80 million
POP BIO	Preclinical	Protein based	Up to \$1.5 million
University of Queensland	Preclinical	Protein based	Up to \$10.6 million
SK Bioscience	Preclinical	mRNA	Up to \$40 million
VitriVax	Preclinical	Inactivated virus/Protein based	Up to \$5 million



**Broadly protective
Filovirus vaccines**

AdaptVac	Preclinical	Virus-like particle	Up to \$12.4 million
----------	-------------	---------------------	----------------------

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.